Welcome to our dedicated page for GeneDx Holdings SEC filings (Ticker: WGSWW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
GeneDx Holdings Corp. filings document the regulatory record for a genomics diagnostics company focused on pediatric and rare disease testing, including whole exome and genome sequencing. Form 8-K reports include quarterly and annual financial results, earnings presentation exhibits, statement presentation changes, non-GAAP measure methodology, and material financing agreements.
The company's disclosures also cover its capital structure, including Class A common stock and Nasdaq-listed warrants under WGSWW. Proxy materials address executive compensation, equity awards, shareholder voting matters, and other governance items, while debt filings describe term-loan arrangements, guarantor subsidiaries, use of proceeds, repayment obligations, and default provisions.
GeneDx Holdings Corp. director Jason Ryan reported an equity award vesting and related share movements. He exercised 3,576 restricted stock units into 3,576 shares of Class A common stock at no cost, increasing his direct holdings to 15,480 shares. He also reports indirect ownership of 103,284 shares held by the Jason Ryan 2024 GRAT, where he serves as trustee and sole annuitant. The RSUs represent a right to receive one share each upon settlement, with vesting tied to the 2026 annual shareholder meeting or the first anniversary of the grant date, subject to continued service.
GeneDx Holdings Corp. director Jason Ryan reported an equity award vesting and related share movements. He exercised 3,576 restricted stock units into 3,576 shares of Class A common stock at no cost, increasing his direct holdings to 15,480 shares. He also reports indirect ownership of 103,284 shares held by the Jason Ryan 2024 GRAT, where he serves as trustee and sole annuitant. The RSUs represent a right to receive one share each upon settlement, with vesting tied to the 2026 annual shareholder meeting or the first anniversary of the grant date, subject to continued service.
GeneDx Holdings director Joshua Ruch reported equity-based compensation activity and updated holdings in Class A Common Stock. He exercised previously awarded restricted stock units (RSUs) covering 3,576 shares at no cost, increasing his directly held common stock to 33,299 shares.
He also received a new grant of 4,248 RSUs, each representing a right to receive one share of Class A Common Stock for no consideration. This award vests on the earlier of the 2027 annual stockholders’ meeting or the first anniversary of the grant date, subject to continued service. Entities associated with him hold additional indirect positions in GeneDx shares, for which he may be deemed to share voting and investment discretion, while disclaiming beneficial ownership beyond any pecuniary interest.
GeneDx Holdings director Joshua Ruch reported equity-based compensation activity and updated holdings in Class A Common Stock. He exercised previously awarded restricted stock units (RSUs) covering 3,576 shares at no cost, increasing his directly held common stock to 33,299 shares.
He also received a new grant of 4,248 RSUs, each representing a right to receive one share of Class A Common Stock for no consideration. This award vests on the earlier of the 2027 annual stockholders’ meeting or the first anniversary of the grant date, subject to continued service. Entities associated with him hold additional indirect positions in GeneDx shares, for which he may be deemed to share voting and investment discretion, while disclaiming beneficial ownership beyond any pecuniary interest.
GeneDx Holdings Corp. director Richard C. Pfenniger Jr. reported equity compensation changes involving Class A Common Stock and restricted stock units. He exercised 3,576 restricted stock units into the same number of Class A shares, increasing his direct holdings to 45,082 shares after the transaction.
On the same date, he received a new grant of 4,248 restricted stock units, each representing a right to one share of Class A Common Stock for no cash consideration. According to the terms, the new RSU award vests in full on the earlier of the 2027 annual stockholders’ meeting or the first anniversary of the grant date, subject to continued service.
GeneDx Holdings Corp. director Richard C. Pfenniger Jr. reported equity compensation changes involving Class A Common Stock and restricted stock units. He exercised 3,576 restricted stock units into the same number of Class A shares, increasing his direct holdings to 45,082 shares after the transaction.
On the same date, he received a new grant of 4,248 restricted stock units, each representing a right to one share of Class A Common Stock for no cash consideration. According to the terms, the new RSU award vests in full on the earlier of the 2027 annual stockholders’ meeting or the first anniversary of the grant date, subject to continued service.
GeneDx Holdings Corp. director and 10% owner Keith A. Meister reported equity compensation activity involving Class A Common Stock and restricted stock units. On June 18, 2026, 3,576 RSUs were exercised, converting into 3,576 shares of Class A Common Stock, bringing his direct holdings of this stock to 23,705 shares.
On the same date, he received a new grant of 4,248 restricted stock units, each representing one share of Class A Common Stock upon settlement for no consideration. This award vests on the earlier of the 2027 annual stockholder meeting or the first anniversary of the grant date, subject to continued service. Separate from these grants, investment funds advised by Corvex Management LP hold 333,144 shares, and CMLS Holdings LLC holds 4,784,570 shares, over which Meister shares or may be deemed to share investment discretion.
GeneDx Holdings Corp. director and 10% owner Keith A. Meister reported equity compensation activity involving Class A Common Stock and restricted stock units. On June 18, 2026, 3,576 RSUs were exercised, converting into 3,576 shares of Class A Common Stock, bringing his direct holdings of this stock to 23,705 shares.
On the same date, he received a new grant of 4,248 restricted stock units, each representing one share of Class A Common Stock upon settlement for no consideration. This award vests on the earlier of the 2027 annual stockholder meeting or the first anniversary of the grant date, subject to continued service. Separate from these grants, investment funds advised by Corvex Management LP hold 333,144 shares, and CMLS Holdings LLC holds 4,784,570 shares, over which Meister shares or may be deemed to share investment discretion.
GeneDx Holdings Corp. director Emily M. Leproust increased her equity stake through routine stock-based compensation. On June 18, 2026, she exercised 3,576 Restricted Stock Units (RSUs), receiving the same number of shares of Class A Common Stock for no cash consideration, bringing her direct holdings to 24,852 shares.
She also received a new grant of 4,248 RSUs, each representing a contingent right to one share of Class A Common Stock upon settlement. According to the award terms, this grant vests on the earlier of the 2027 annual stockholder meeting or the first anniversary of the grant date, subject to her continued service.
GeneDx Holdings Corp. director Emily M. Leproust increased her equity stake through routine stock-based compensation. On June 18, 2026, she exercised 3,576 Restricted Stock Units (RSUs), receiving the same number of shares of Class A Common Stock for no cash consideration, bringing her direct holdings to 24,852 shares.
She also received a new grant of 4,248 RSUs, each representing a contingent right to one share of Class A Common Stock upon settlement. According to the award terms, this grant vests on the earlier of the 2027 annual stockholder meeting or the first anniversary of the grant date, subject to her continued service.
Fuchs Thomas reported acquisition or exercise transactions in this Form 4 filing.
GeneDx Holdings Corp. director Thomas Fuchs received an equity compensation award in the form of 4,248 restricted stock units on June 18, 2026. Each RSU represents a contingent right to receive one share of Class A common stock upon settlement for no cash payment.
The entire award will vest on the earlier of the company’s 2027 annual stockholder meeting or the first anniversary of the grant date, as long as Fuchs continues to serve the company through that date. If service ends before vesting, the units may be cancelled rather than vest. Following this grant, Fuchs is reported as holding 4,248 RSUs, and no open‑market purchases or sales are disclosed in this filing.
Fuchs Thomas reported acquisition or exercise transactions in this Form 4 filing.
GeneDx Holdings Corp. director Thomas Fuchs received an equity compensation award in the form of 4,248 restricted stock units on June 18, 2026. Each RSU represents a contingent right to receive one share of Class A common stock upon settlement for no cash payment.
The entire award will vest on the earlier of the company’s 2027 annual stockholder meeting or the first anniversary of the grant date, as long as Fuchs continues to serve the company through that date. If service ends before vesting, the units may be cancelled rather than vest. Following this grant, Fuchs is reported as holding 4,248 RSUs, and no open‑market purchases or sales are disclosed in this filing.
GeneDx Holdings Corp. director and 10% owner Eli Casdin reported equity compensation activity involving GeneDx Class A Common Stock and restricted stock units. He exercised 3,576 RSUs into 3,576 shares of Class A Common Stock at no cost, increasing his direct common share holdings to 24,093 shares.
Casdin also received a new grant of 4,248 RSUs, each representing one future share of Class A Common Stock, which will vest on the earlier of the 2027 annual stockholder meeting or the first anniversary of the grant date, subject to continued service. In addition, entities associated with Casdin hold substantial indirect positions, including 3,707,164 shares through Casdin Partners Master Fund, LP, 333,144 shares through CMLS Holdings LLC, and 19,247 shares through Casdin Partners GP, LLC.
GeneDx Holdings Corp. director and 10% owner Eli Casdin reported equity compensation activity involving GeneDx Class A Common Stock and restricted stock units. He exercised 3,576 RSUs into 3,576 shares of Class A Common Stock at no cost, increasing his direct common share holdings to 24,093 shares.
Casdin also received a new grant of 4,248 RSUs, each representing one future share of Class A Common Stock, which will vest on the earlier of the 2027 annual stockholder meeting or the first anniversary of the grant date, subject to continued service. In addition, entities associated with Casdin hold substantial indirect positions, including 3,707,164 shares through Casdin Partners Master Fund, LP, 333,144 shares through CMLS Holdings LLC, and 19,247 shares through Casdin Partners GP, LLC.
GeneDx Holdings Corp. reported the results of its Annual Meeting of Stockholders held on June 18, 2026. Stockholders elected Class II director Katherine Stueland to a three-year term, with 18,325,894 votes for and 5,893,466 votes withheld, and 3,409,327 broker non-votes.
Stockholders ratified Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, with 27,466,639 votes for, 158,884 against and 3,164 abstentions. They also approved, on an advisory basis, the compensation of named executive officers, with 22,705,946 votes for and 1,471,593 against.
In an advisory vote on how often to hold future say-on-pay votes, 23,816,121 votes favored an annual vote, 24,246 favored every two years, 358,017 favored every three years, and 20,976 abstained. There were 29,675,547 Class A shares outstanding on the April 20, 2026 record date.
GeneDx Holdings Corp. reported the results of its Annual Meeting of Stockholders held on June 18, 2026. Stockholders elected Class II director Katherine Stueland to a three-year term, with 18,325,894 votes for and 5,893,466 votes withheld, and 3,409,327 broker non-votes.
Stockholders ratified Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, with 27,466,639 votes for, 158,884 against and 3,164 abstentions. They also approved, on an advisory basis, the compensation of named executive officers, with 22,705,946 votes for and 1,471,593 against.
In an advisory vote on how often to hold future say-on-pay votes, 23,816,121 votes favored an annual vote, 24,246 favored every two years, 358,017 favored every three years, and 20,976 abstained. There were 29,675,547 Class A shares outstanding on the April 20, 2026 record date.
GeneDx Holdings Corp. chief financial officer Kevin Feeley reported an RSU vesting and related share sales to cover taxes. On June 16, 2026, 7,197 restricted stock units converted into an equal number of Class A Common shares for no cash consideration.
To fund tax withholding on this vesting, he sold a total of 3,729 Class A Common shares in open-market transactions at weighted-average prices between about $59 and $62 per share. After these sales, he beneficially owned 39,954 shares, plus RSUs covering up to 82,043 shares and options for up to 25,906 shares, all vesting under their existing terms.
GeneDx Holdings Corp. chief financial officer Kevin Feeley reported an RSU vesting and related share sales to cover taxes. On June 16, 2026, 7,197 restricted stock units converted into an equal number of Class A Common shares for no cash consideration.
To fund tax withholding on this vesting, he sold a total of 3,729 Class A Common shares in open-market transactions at weighted-average prices between about $59 and $62 per share. After these sales, he beneficially owned 39,954 shares, plus RSUs covering up to 82,043 shares and options for up to 25,906 shares, all vesting under their existing terms.
GeneDx Holdings Corp. CEO Katherine Stueland reported routine equity compensation activity and related tax sales. On June 16, 2026, she exercised restricted stock units, acquiring 18,750 shares of Class A Common Stock upon RSU vesting.
On the same date she sold a total of 10,501 shares of Class A Common Stock in open-market transactions at weighted average prices around $59.75–$61.50 per share to cover tax withholding obligations from the RSU vesting, described as a non-discretionary “sell to cover” transaction. After these transactions, she beneficially owned 104,372 shares of Class A Common Stock, plus RSUs for up to 305,525 shares and options for up to 107,610 shares that vest under their terms.
GeneDx Holdings Corp. CEO Katherine Stueland reported routine equity compensation activity and related tax sales. On June 16, 2026, she exercised restricted stock units, acquiring 18,750 shares of Class A Common Stock upon RSU vesting.
On the same date she sold a total of 10,501 shares of Class A Common Stock in open-market transactions at weighted average prices around $59.75–$61.50 per share to cover tax withholding obligations from the RSU vesting, described as a non-discretionary “sell to cover” transaction. After these transactions, she beneficially owned 104,372 shares of Class A Common Stock, plus RSUs for up to 305,525 shares and options for up to 107,610 shares that vest under their terms.